Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma
Authors:
- 21 July 2022
- journal article
- research article
- Published by Springer Nature in European Radiology
- Vol. 33 (1) , 512-522
Abstract
Objectives To investigate the association of sarcopenia, myosteatosis, and sarcopenic obesity with survival outcomes among patients who underwent immunotherapy for advanced hepatocellular carcinoma (HCC). Methods In this retrospective analysis, patients who initiated immunotherapy for advanced HCC were enrolled. Sarcopenia and myosteatosis were evaluated on pretreatment CT at L3 level by skeletal muscle index and mean muscle attenuation using predefined cutoff values. Sarcopenic obesity was defined as concurrent sarcopenia and body mass index > 25 kg/m2. The log-rank test and the Cox proportional hazards model were used to compare overall survival (OS) and progression-free survival (PFS). Results A total of 138 patients was included (discovery cohort n = 111, validation cohort n = 27). In the discovery cohort, patients with sarcopenia exhibited significantly poorer PFS (p = 0.048) and OS (p = 0.002) than patients without sarcopenia. Patients with myosteatosis exhibited significantly poorer PFS (p < 0.001) and OS (p < 0.001) than patients without myosteatosis. Patients with sarcopenic obesity compared to patients without sarcopenic obesity exhibited significantly poorer OS (p = 0.006) but not PFS (p = 0.31). In multivariate analysis adjusting for patient demographics, tumor extent, and liver function reserve, myosteatosis remained an independent predictor of poor PFS (p = 0.014) and OS (p = 0.007); sarcopenia remained an independent predictor for poor OS (p = 0.007). The prediction models for survival outcomes built by the discovery cohort showed similar performance in the validation cohort. Conclusions Sarcopenia and myosteatosis are independent prognostic factors in patients who received immunotherapy for advanced HCC. Key Points • Sarcopenia and myosteatosis can be evaluated by CT at L3 level. • Sarcopenia, myosteatosis, and sarcopenic obesity were associated with poor survival outcomes in patients who underwent immunotherapy for advanced HCC. • Myosteatosis was an independent predictor of PFS and OS, and sarcopenia was independent for OS in these patients.Keywords
Funding Information
- Ministry of Science and Technology (MOST-103-2314-B-002-181-MY2, MOST-105-2314-B-002-194, MOST 106-2314-B-002-213, MOST-108-2314-B-002-072-MY3, MOST-110-2314-B-002-144)
- Ministry of Health and Welfare (MOHW109-TDU-B-211-114002)
- National Taiwan University Hospital (NTUH 105S2954, and NTUH 108-S4150)
- the Good Liver Foundation, Taiwan
This publication has 38 references indexed in Scilit:
- Contrast-enhancement influences skeletal muscle density, but not skeletal muscle mass, measurements on computed tomographyClinical Nutrition, 2018
- Optimal Cutoff Values of Skeletal Muscle Index to Define Sarcopenia for Prediction of Survival in Patients with Advanced Gastric CancerAnnals of Surgical Oncology, 2018
- Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategiesNature Reviews Endocrinology, 2018
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialThe Lancet Oncology, 2018
- Preoperative Visceral Adiposity and Muscularity Predict Poor Outcomes after Hepatectomy for Hepatocellular CarcinomaLiver Cancer, 2018
- Sarcopenia and myosteatosis are accompanied by distinct biological profiles in patients with pancreatic and periampullary adenocarcinomasPLOS ONE, 2018
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialThe Lancet, 2017
- Impact of different sarcopenia stages on the postoperative outcomes after radical gastrectomy for gastric cancerSurgery, 2017
- Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapyEuropean Journal of Cancer, 2016
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011